Clinical treatment of erectile dysfunction in type 2 diabeticpatients in the high-altitude area.
- Author:
Fu-Dong LI
1
;
Bin ZHANG
2
;
Yang-Min WANG
2
Author Information
1. The Second School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu 730030, China.
2. Department of Urology, Lanzhou General Hospital of PLA, Lanzhou, Gansu 730050, China.
- Publication Type:Journal Article
- Keywords:
erectile dysfunction;
pancreatic kininogenase;
sildenafil;
type 2 diabetes mellitus;
high-altitude area
- MeSH:
Aged;
Altitude;
Coitus;
Diabetes Mellitus, Type 2;
complications;
Drug Therapy, Combination;
Erectile Dysfunction;
etiology;
therapy;
Humans;
Kallikreins;
therapeutic use;
Male;
Pancreas;
enzymology;
Penile Erection;
drug effects;
physiology;
Penis;
physiology;
Phosphodiesterase 5 Inhibitors;
therapeutic use;
Sildenafil Citrate;
therapeutic use;
Treatment Outcome
- From:
National Journal of Andrology
2017;23(10):878-882
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of pancreatic kininogenase combined with sildenafil in the treatment of erectile dysfunction(ED) in type 2 diabetes mellitus (DM) patients in the high-altitude area.
METHODS:This study included 93 ED patients with type 2 DM, all residents of the Xining area 1500 meters above sea level. We randomly divided them into an experimental group (n = 48) and a control group (n = 45), the former treated with pancreatic kininogenase(120 u, tid) and sildenafil (25 mg, qd at bedtime), while the latter with sildenafil only (25 mg, qd at bedtime).After 4 and 8 weeks of medication, we obtained the penile hemodynamic parameters,IIEF-5 scores, and sexual intercourse satisfaction(SIS) scores and compared them between the two groups of patients.
RESULTS:There were no statistically significant differences in age or DM course between the two groups of patients (P >0.05).Compared with the baseline, both the experimental and control groups showed remarkably improvement inthe IIEF-5 score (8.81 ± 2.06 vs 11.54 ± 7.72 and 8.29 ± 1.91 vs 9.37± 1.65, P <0.05), SIS score (3.35 ± 2.43vs6.83± 2.61and 3.41 ± 2.38 vs 4.92± 2.49, P <0.05), and penile hemodynamic parameters obtained by color duplex Doppler ultrasonography(P <0.05), with significant differences between the two groups in the IIEF-5 score (11.54 ± 7.72 vs 9.37± 1.65, P <0.05) and SIS score (6.83± 2.61 vs 4.92± 2.49, P <0.05) but not in the penile hemodynamic parameters (P >0.05). Even more remarkable improvement was observed at 8 weeks in the experimental and control groups in the IIEF-5 score (19.29± 1.85 and 15.43± 1.74)(P <0.05), SIS score (11.73 ± 2.57 and 6.55± 2.71) (P <0.05), and penile hemodynamic parameters(P <0.05), all with significant differences between the two groups (P <0.05).
CONCLUSIONS:Pancreatic kininogenase combined with sildenafil has a better clinical effect than sildenafil alone on ED in type 2 DM patientsin the high-altitude area.
